Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|November 6, 2014
Confidence Interval Estimation for Sensitivity to the Early Diseased Stage Based on Empirical LikelihoodTuochuan Dong, Lili Tian
Statistics in Medicine|December 6, 2011
Parametric and non-parametric confidence intervals of the probability of identifying early disease stage given sensitivity to full disease and specificity with three ordinal diagnostic groupsTuochuan Dong, Lili Tian, Alan Hutson, et al.
Statistical Methods in Medical Research|October 22, 2015
A new diagnostic accuracy measure and cut-point selection criterionTuochuan Dong, Kristopher Attwood, Alan Hutson, et al.
Biometrical Journal. Biometrische Zeitschrift|November 23, 2013
Confidence interval estimation of the difference between two sensitivities to the early disease stageTuochuan Dong, Le Kang, Alan Hutson, et al.
Anticancer Research|October 30, 2016
Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid TumorsYi-Long Wu, L I Zhang, Lucia Trandafir, et al.
NEJM Evidence|June 25, 2024
Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 DiabetesJason L Gaglia, Heather L Daley, Nora K Bryant, et al.
Blood Advances|July 8, 2020
Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding studyVikas Gupta, Denise Wolleschak, Hans Hasselbalch, et al.
Journal of Hematology & Oncology|October 1, 2017
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analysesSrdan Verstovsek, Jason Gotlib, Ruben A Mesa, et al.
Future Oncology (London, England)|March 2, 2021
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study designPilar Garrido, Jean-Louis Pujol, Edward S Kim, et al.
The Lancet. Haematology|January 27, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyJean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, et al.
Pageof 1